Why do sponsors use hierarchical testing procedures for secondary endpoints?

Testing multiple secondary endpoints without correction inflates the trial-wide false-positive rate, so sponsors pre-specify a fixed-sequence or alpha-splitting hierarchy in which a secondary endpoint is only tested for statistical significance after the primary (and any higher-ranked secondary endpoints) achieves significance. This hierarchical gatekeeping, described in ICH E9 and FDA's multiple endpoints guidance, is what allows a device manufacturer to claim multiple labelable benefits from a single pivotal trial without inflating type I error.

What is an estimand and why does it matter for endpoint definition?

An estimand, introduced by the ICH E9(R1) addendum, precisely defines the treatment effect a trial is designed to estimate, specifying the population, the variable (endpoint), how intercurrent events (like treatment discontinuation or rescue therapy) are handled, and the population-level summary measure. Defining the estimand alongside the primary endpoint prevents post hoc disputes about how missing data or protocol deviations should be handled in the primary analysis, which is a frequent source of disagreement between sponsors and FDA statisticians.

What is the most common mistake sponsors make with endpoint selection?

The most common mistake is choosing a composite primary endpoint without pre-specifying how component events will be weighted, adjudicated, and analyzed if results are directionally inconsistent across components, which can produce a technically 'positive' trial that FDA or clinicians view as clinically ambiguous. Composite endpoints like MACE in cardiovascular device trials require a detailed adjudication charter and component-level reporting plan established before unblinding.

Back to Clinical Trials & Evidence

Clinical & TrialsClinical Evidence

Primary and Secondary Endpoints

The pre-specified outcomes that determine trial success (primary), provide supporting evidence (secondary), or generate hypotheses (exploratory).

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

The primary endpoint is the pre-specified outcome on which the trial is statistically powered and on which trial success or failure is judged. Secondary endpoints provide supporting evidence, additional efficacy claims, safety, or quality-of-life, and are typically tested under a pre-specified hierarchical or alpha-allocation procedure to control multiplicity. Exploratory endpoints generate hypotheses for future studies and do not support label or coverage claims. Endpoint choice and ordering is the single most consequential design decision in a pivotal trial.

What the regulation says

ICH E9 'Statistical Principles for Clinical Trials' and ICH E9(R1) addendum on Estimands govern endpoint specification. FDA's 'Multiple Endpoints in Clinical Trials' guidance (2022) details multiplicity control.

What this means in practice

MedTech sponsors increasingly use composite primary endpoints (MACE in cardiovascular, KCCQ in heart failure) and pre-specify hierarchical secondary testing to maximize labelable claims.

Examples

In a trial evaluating a novel glucose monitoring system, the primary endpoint might be the mean absolute relative difference (MARD) compared to a laboratory reference, while a secondary endpoint could be the reduction in hypoglycemic events.
A MedTech study for a new surgical device could establish the primary endpoint as successful implantation without complications, with secondary endpoints including post-operative pain scores and length of hospital stay.
For a diagnostic imaging AI algorithm, the primary endpoint might be its sensitivity and specificity in detecting a specific condition, with a secondary endpoint focusing on the reduction in radiologist interpretation time.

Common pitfalls

•Adding endpoints during trial conduct, almost always destroys their interpretability.
•Failing to control multiplicity across secondary endpoints, leaving label claims unsupported.

Frequently asked questions

The primary endpoint is the single pre-specified outcome (or co-primary set) on which the trial is statistically powered and against which trial success or failure is formally judged, while secondary endpoints provide supporting evidence on additional efficacy, safety, or quality-of-life outcomes and are typically tested through a pre-specified hierarchical or alpha-allocation procedure to control the overall false-positive rate. Exploratory endpoints, by contrast, generate hypotheses for future studies and cannot support labeling or reimbursement claims on their own.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Clinical & Trials

Surrogate Endpoint

Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions.

Clinical & Trials

Pivotal Trial

Definitive clinical study designed to establish safety and effectiveness for marketing authorization.

Clinical & Trials

Composite Endpoint

Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke).

Clinical & Trials

Non-Inferiority Trial

A trial designed to demonstrate that a new intervention is not worse than an active comparator by more than a pre-specified, clinically acceptable margin.

Clinical Trials & Evidence

· From this learning path

Clinical & Trials

Protocol Deviation

Departure from the approved clinical investigation plan.

Adjacent lesson

Clinical & Trials

Adaptive Trial Design

Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.

Clinical & Trials

Adverse Event(AE)

Any untoward medical occurrence in a subject, whether or not related to the device.

Clinical & Trials

Clinical Evaluation Report(CER)

Documented assessment of clinical data demonstrating EU MDR conformity for a device.

Cited by

Where this term appears across MedTech Terms.

Learning paths (1)

Clinical Trials & EvidenceLesson 10 of 18

Ecosystems (1)

Clinical Evidence

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 3

Link health: 3 verified· last checked 2026-06-20

FDA·1ICH·2

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Clinical & Trials0 / 52

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Clinical & Trials
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

The pre-specified outcomes that determine trial success (primary), provide supporting evidence (secondary), or generate hypotheses (exploratory).

·MedTech sponsors increasingly use composite primary endpoints (MACE in cardiovascular, KCCQ in heart failure) and pre-specify hierarchical secondary testing to maximize labelable claims.
·Exploratory endpoints generate hypotheses for future studies and do not support label or coverage claims.

Remember this

Watch out: Adding endpoints during trial conduct, almost always destroys their interpretability.

Related terms

You may also need

Auto-suggested from Clinical & Trials and shared keywords.

All Clinical & Trials terms

From the Blue Goat network

Related resources and services on this topic.

MedTech Launchpad
MedTech funding rounds, accelerators, and launch resources.